Syed Taha Iqbal

Array ( [id] => 16642110 [patent_doc_number] => 10919946 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the PFR1 protein of leishmania infantum with specific immunodominant epitopes [patent_app_type] => utility [patent_app_number] => 15/895907 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 23 [patent_no_of_words] => 8193 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 291 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16215136 [patent_doc_number] => 10730934 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-04 [patent_title] => Antibodies to [patent_app_type] => utility [patent_app_number] => 15/880157 [patent_app_country] => US [patent_app_date] => 2018-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 27 [patent_no_of_words] => 33685 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15880157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314285 [patent_doc_number] => 20180208679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins [patent_app_type] => utility [patent_app_number] => 15/870351 [patent_app_country] => US [patent_app_date] => 2018-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15870351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314287 [patent_doc_number] => 20180208680 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => Antibodies for Botulinum Neurotoxins [patent_app_type] => utility [patent_app_number] => 15/870635 [patent_app_country] => US [patent_app_date] => 2018-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15870635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12904780 [patent_doc_number] => 20180193435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => HYBRID NEUROTOXINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/866895 [patent_app_country] => US [patent_app_date] => 2018-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15866895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12702373 [patent_doc_number] => 20180125957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => IMMUNOGENIC COMPOSITION COMPRISING MYCOPLASMA ANTIGENS [patent_app_type] => utility [patent_app_number] => 15/846975 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15846975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15281795 [patent_doc_number] => 10513552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-24 [patent_title] => Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease [patent_app_type] => utility [patent_app_number] => 15/845214 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 12717 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15845214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993421 [patent_doc_number] => 20200172581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => COMPOSITIONS AND METHODS TO TREAT CANCER WITH CpG RICH DNA AND CUPREDOXINS [patent_app_type] => utility [patent_app_number] => 15/837066 [patent_app_country] => US [patent_app_date] => 2017-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15837066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13476451 [patent_doc_number] => 20180289768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => ANTIMICROBIAL AND ANTI-INFLAMMATORY PEPTIDES [patent_app_type] => utility [patent_app_number] => 15/835154 [patent_app_country] => US [patent_app_date] => 2017-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20060 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15835154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493297 [patent_doc_number] => 20200046837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => UROGENITAL MEDICAL DEVICE FORMULATION BASED ON SUITABLE BIOCHEMICAL COMPOSITIONS FOR THE STABILIZATION OF THE ACIDITY AND THE REDOX STATE OF THE VAGINAL FLUID [patent_app_type] => utility [patent_app_number] => 16/465208 [patent_app_country] => US [patent_app_date] => 2017-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13267 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786463 [patent_doc_number] => 20180153990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => PCA1 PROTEIN AND METHODS OF TREATING PNEUMOCYSTIS PNEUMONIA INFECTION [patent_app_type] => utility [patent_app_number] => 15/826297 [patent_app_country] => US [patent_app_date] => 2017-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15826297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14003303 [patent_doc_number] => 10220079 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-05 [patent_title] => Suture line administration technique using botulinum toxins [patent_app_type] => utility [patent_app_number] => 15/822573 [patent_app_country] => US [patent_app_date] => 2017-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 14660 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15822573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16310874 [patent_doc_number] => 20200289612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => COMBINED CD6 AND IMIPENEM THERAPY FOR TREATMENT OF INFECTIOUS DISEASES AND RELATED INFLAMMATORY PROCESSES [patent_app_type] => utility [patent_app_number] => 16/462099 [patent_app_country] => US [patent_app_date] => 2017-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16462099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12675889 [patent_doc_number] => 20180117129 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => NEUROTOXINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/793628 [patent_app_country] => US [patent_app_date] => 2017-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4330 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15793628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185741 [patent_doc_number] => 20180044678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'DOUBLE-STRANDED RIBONUCLEIC ACID FOR ADJUVANTS' [patent_app_type] => utility [patent_app_number] => 15/791742 [patent_app_country] => US [patent_app_date] => 2017-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10960 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15791742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17268511 [patent_doc_number] => 11193931 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Cellular vamp cleavage assay [patent_app_type] => utility [patent_app_number] => 16/335358 [patent_app_country] => US [patent_app_date] => 2017-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 16542 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14682345 [patent_doc_number] => 20190240287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => INHIBITOR OF RNA POLYMERASE II [patent_app_type] => utility [patent_app_number] => 16/341962 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12151520 [patent_doc_number] => 20180022783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/728610 [patent_app_country] => US [patent_app_date] => 2017-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 27350 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15728610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12184064 [patent_doc_number] => 20180043000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'TREATMENT OF SOCIAL ANXIETY DISORDER, OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER USING BOTULINUM TOXIN' [patent_app_type] => utility [patent_app_number] => 15/725178 [patent_app_country] => US [patent_app_date] => 2017-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10576 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15725178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14932955 [patent_doc_number] => 20190302115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => METHOD FOR REMOVING INHIBITORY COMPONENTS [patent_app_type] => utility [patent_app_number] => 16/336617 [patent_app_country] => US [patent_app_date] => 2017-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16336617 [rel_patent_id] =>[rel_patent_doc_number] =>)